This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

King Must Sell Drug Assets to Buy Alpharma

Stocks in this article: ALO

By Marley Seaman

BRISTOL, Tenn. -- King Pharmaceuticals (KG)said Friday it will be allowed to buy Alpharma (ALO)provided it sells some assets related to Alpharma's painkiller Kadian.

King said the Federal Trade Commission has ended a required waiting period for King's buyout of Alpharma and is provisionally accepting a consent order for public comment. After three months of public wrangling, Alpharma accepted a buyout offer worth $1.6 billion, or $37 per share, from King in November.

King's tender offer for Bridgewater, N.J.-based Alpharma is expected to end at 10 a.m. Monday, and more than 92% of Alpharma shares have been tendered in favor of the deal.

Kadian is an extended-release morphine-based pain drug, and in 2007, it was Alpharma's best-seller, bringing in $167.7 million in revenue. King is developing its own extended-release painkiller, called Remoxy, with Pain Therapeutics. Remoxy is a form of oxycodone, an opioid marketed as OxyContin, that is designed to be abuse-resistant.

King gets about half its revenue from sales of painkillers, but its muscle relaxant Skelaxin will face generic competition in 2012, and analysts say the patents supporting the drug could be overturned as early as 2009. The company lost patent protection on its blood pressure drug Altace in 2007, and its surgical blood-clotting product Thrombin-JMI is also facing patent threats.

Alpharma also makes the Flector pain patch, which it began selling in January.

The patents behind Kadian are scheduled to expire in spring 2010. Cowen and Co. analyst Ian Sanderson said the FTC's ruling is "a positive outcome for King" because the company won't have to sell off a more valuable product or drug candidate.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs